Cargando…
PD-L2 based immune signature confers poor prognosis in HNSCC
PD-L2 expression is an important predictor of anti-PD-1 therapy efficacy in patients with head and neck squamous cell carcinoma (HNSCC). However, whether the PD-L2-based immune signature can serve as a prognostic biomarker for patients with HNSCC remains unclear. Here, we reported that PD-L2 was pos...
Autores principales: | Qiao, Yu, Liu, Chao, Zhang, Xiaoyue, Zhou, Qianqian, Li, Yatian, Xu, Yini, Gao, Zhenyue, Xu, Yiqi, Kong, Lingping, Yang, Aifeng, Mei, Mei, Ren, Yu, Wang, Xudong, Zhou, Xuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344752/ https://www.ncbi.nlm.nih.gov/pubmed/34377590 http://dx.doi.org/10.1080/2162402X.2021.1947569 |
Ejemplares similares
-
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021) -
Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC
por: Zhou, Xuan, et al.
Publicado: (2015) -
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
por: Wang, Yuqing, et al.
Publicado: (2022) -
CD73 is associated with poor prognosis in HNSCC
por: Ren, Zhen-Hu, et al.
Publicado: (2016) -
Decreased calpain 6 expression is associated with tumorigenesis and poor prognosis in HNSCC
por: Xiang, Yinzhou, et al.
Publicado: (2017)